Horiuchi Hiroyuki, Nogita Hidefumi, Kawashima Yusuke, Kitazato Yuhei, Akashi Masakane, Akasu Gen, Mikagi Kazuhiro, Kawahara Ryuichi, Ishikawa Hiroto, Hisaka Tohru, Kinoshita Hisafumi, Shirouzu Kazuo, Okabe Yoshinobu
Dept. of Surgery, Kurume University School of Medicine.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2087-9.
We schemed intraperitoneal gemcitabine (ipGEM) for reduction of peritoneal dissemination to three patients with unresectable and one patient with recurrent pancreatic cancer, followed by intraperitoneal catheter and subcutaneous port placement. Two locally advanced cases were performed for intra-operative radiotherapy, and one of 2 locally advanced cases was performed for gastrojejunostomy. And another locally advanced case had ileostomy. The recurrent case was resected for metastatic tumor of abdominal wall. In one of locally advanced cases, we couldn't perform ipGEM for progression of disease. In two remaining locally advanced cases, we could keep on doing ipGEM, and the patients did not experience with abdominal discomfort or hematological toxicity.
我们对3例无法切除的胰腺癌患者和1例复发性胰腺癌患者采用腹腔内吉西他滨（ipGEM）治疗以减少腹膜播散，随后放置腹腔内导管和皮下端口。对2例局部晚期病例进行了术中放疗，2例局部晚期病例中的1例进行了胃空肠吻合术。另一例局部晚期病例进行了回肠造口术。对复发性病例切除了腹壁转移瘤。在1例局部晚期病例中，因疾病进展无法进行ipGEM治疗。在其余2例局部晚期病例中，我们能够继续进行ipGEM治疗，患者未出现腹部不适或血液学毒性。
